Skip to main content

ST Segment Elevation Myocardial Infarction

3
Pipeline Programs
7
Companies
5
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
2
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Chiesi
KENGREALApproved
cangrelor
Chiesi
P2Y12 Platelet Inhibitor [EPC]intravenous2015

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Chiesi
ChiesiBrazil - Santana de Parnaíba
1 program
1
CangrelorPhase 41 trial
Active Trials
NCT03247738Completed50Est. Dec 2018
Lisata Therapeutics
Lisata TherapeuticsNJ - Basking Ridge
1 program
1
NBS10Phase 21 trial
Active Trials
NCT01495364Completed195Est. Apr 2016
Philips
PhilipsNetherlands - Amsterdam
1 program
BAMA solutionN/A1 trial
Active Trials
NCT03565978Completed300Est. Jul 2018
Abbott
AbbottABBOTT PARK, IL
1 program
China STEMI-PCI ProgramN/A1 trial
Active Trials
NCT01716884Unknown4,000Est. Jun 2016
Sanofi
SanofiPARIS, France
1 program
China STEMI-PCI ProgramN/A
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
Nitroprusside SodiumN/A1 trial
Active Trials
NCT03406819UnknownEst. Dec 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
ChiesiCangrelor
Lisata TherapeuticsNBS10
City TherapeuticsNitroprusside Sodium
PhilipsBAMA solution
AbbottChina STEMI-PCI Program

Clinical Trials (5)

Total enrollment: 4,545 patients across 5 trials

NCT03247738ChiesiCangrelor

Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI

Start: Nov 2017Est. completion: Dec 201850 patients
Phase 4Completed
NCT01495364Lisata TherapeuticsNBS10

NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction

Start: Dec 2011Est. completion: Apr 2016195 patients
Phase 2Completed
NCT03406819City TherapeuticsNitroprusside Sodium

Prevention of Coronary Slow Flow or No-Reflow During PPCI in Patients With Acute STEMI

Start: Jan 2018Est. completion: Dec 2019
N/AUnknown
NCT03565978PhilipsBAMA solution

Cardiac Care Solution for Coronary Disease Follow up

Start: Apr 2016Est. completion: Jul 2018300 patients
N/ACompleted
NCT01716884AbbottChina STEMI-PCI Program

China STEMI-PCI Program

Start: Dec 2011Est. completion: Jun 20164,000 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.